Scarica l'app Stockscreener
1.27
1.60%
0.02
Dopo l'orario di chiusura:
1.30
0.03
+2.36%
Precedente Chiudi:
$1.25
Aprire:
$1.22
Volume 24 ore:
30,456
Relative Volume:
0.19
Capitalizzazione di mercato:
$36.62M
Reddito:
$40.58M
Utile/perdita netta:
$-80.65M
Rapporto P/E:
-0.3813
EPS:
-3.331
Flusso di cassa netto:
$-8.11M
1 W Prestazione:
+0.00%
1M Prestazione:
-5.22%
6M Prestazione:
-42.79%
1 anno Prestazione:
-23.95%
Intervallo 1D:
$1.21
$1.28
Intervallo di 1 settimana:
$1.18
$1.34
Portata 52W:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.27 | 36.05M | 40.58M | -80.65M | -8.11M | -3.331 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
NEXGEL to pay $15 million for Celularity regenerative biomaterial portfolio - MSN
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Sells and Licenses Biomaterials Portfolio to NexGel in Deal Worth Up to $35 Million - TradingView
Celularity (Nasdaq: CELU) monetizes biomaterials in $35M license, pivots to longevity - Stock Titan
Biotechnology company Celularity Inc. recently announced a significant personnel change. - Bitget
NEXGEL, Inc. to Acquire Regenerative Biomaterial Portfolio from Celularity, Anticipating Tripled Revenue and Immediate Profitability - Quiver Quantitative
Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars. - Bitget
NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire
Celularity Inc. Announces Strategic Partnership to Commercialize Biomaterials Portfolio, Generating Up to $35 Million in Payments - Quiver Quantitative
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
NEXGEL grabs Celularity biomaterials in move expected to turn a profit - Stock Titan
Celularity names John Sprague acting CFO following executive departure - Investing.com Nigeria
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Celularity Inc a defensive stockPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Will Celularity Inc. stock reach all time highs in 2026Weekly Loss Report & Reliable Price Action Trade Plans - Naître et grandir
Take Profit: Is Celularity Inc Equity Warrant impacted by rising ratesJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Aug Shorts: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Celularity names John Sprague acting CFO following executive departure By Investing.com - Investing.com India
Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026SEC Filing - TradingView
Celularity Inc Announces Departure of Joseph Dossantos as Svp, Finance, Effective February 27, 2026 - marketscreener.com
Celularity Inc. Shares Seek Catalysts Amid Sector-Watch Phase () - aktiencheck.de
CELU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CELUW SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):